MicroBiopharm Acquired by Gujarat Themis Biosyn | Healthcare M&A Deal

Gujarat Themis Biosyn has acquired MicroBiopharm, a medical devices business in Japan, for $X. MicroBiopharm acquisition strengthens Gujarat Themis Biosyn’s healthcare M&A footprint by expanding CDMO capabilities for biopharma manufacturing and development. Gujarat Themis Biosyn acquisitions are positioned to support platform acquisition strategy by adding specialized production capacity and process know-how from MicroBiopharm. The announced strategic acquisition is structured as a platform acquisition, with deal value reported at ₹1300 cr and size over $100M, aimed at accelerating growth in medical devices and related healthcare services.